Valneva (NASDAQ:VALN) Rating Increased to Hold at Wall Street Zen

Valneva (NASDAQ:VALN) was upgraded by Wall Street Zen to a “hold” rating in a report issued on Saturday.

Several other equities analysts have also issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of Valneva in a report on Monday, August 25th. Jefferies Financial Group set a $14.00 price objective on Valneva and gave the stock a “buy” rating in a report on Monday, August 25th. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $15.33.

Valneva Stock Down 2.1%

Valneva stock opened at $8.65 on Friday. Valneva has a 1-year low of $3.62 and a 1-year high of $12.25. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.27 and a quick ratio of 1.77. The stock has a market cap of $736.03 million, a PE ratio of -8.83 and a beta of 1.79. The stock’s fifty day moving average is $8.03 and its two-hundred day moving average is $7.08.

Valneva (NASDAQ:VALN) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.11. Valneva had a negative return on equity of 34.78% and a negative net margin of 33.87%.The company had revenue of $54.84 million for the quarter, compared to analysts’ expectations of $46.28 million. On average, sell-side analysts expect that Valneva will post 0.13 EPS for the current fiscal year.

Hedge Funds Weigh In On Valneva

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Marex Group plc purchased a new position in shares of Valneva during the second quarter worth about $64,000. GAMMA Investing LLC purchased a new position in shares of Valneva during the first quarter worth about $94,000. Finally, Frazier Life Sciences Management L.P. purchased a new position in shares of Valneva during the second quarter worth about $8,240,000. Hedge funds and other institutional investors own 11.39% of the company’s stock.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.